Canaan Inc. has appointed KPMG LLP in Singapore as its new independent auditor, replacing KPMG Huazhen LLP, effective October 19, 2026. This change follows a thorough evaluation and was approved by the company's Audit Committee and Board of Directors. KPMG Singapore will audit Canaan's consolidated financial statements for the year ending December 31, 2026. The move reflects Canaan's expanding global operations and commitment to strong corporate governance and financial transparency as it grows its energy and computing infrastructure business internationally.
Canaan's auditor appointment news provides context for technology sector trends. For readers following Technology-sector US stocks, here is Pluang's market snapshot as of Oct 19, 2026 19:31 WIB: 93 of 150 stocks rose, 46 fell. Notable movers include CRSR at USD 13.40 (+4.77%), MRVL at USD 238.15 (+4.53%), and LRCX at USD 275.68 (+4.45%). Typical hold times range from 25 to 61 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
